Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Multi-specific antibodies and methods of making and using thereof

A specific and binding specific technology, applied in chemical instruments and methods, antibodies, specific peptides, etc.

Active Publication Date: 2020-02-21
SYSTIMMUNE INC +1
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In a case study of patients resistant to blinatumomab therapy, a second round of blinatumomab was administered, but with the addition of a monoclonal agent that was specific for PD-1 and blocked the interaction of PD-1 expressed by T cells with PD-L1 expressed by tumor cells. The cloned antibody Pembrolizumab (Keytruda, Merck), resulted in a significant response and reduction of tumor cells in the bone marrow from 45% to less than 5% in this patient (Feucht et al., 2016, Oncotarget 7(47):76902-76919)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Multi-specific antibodies and methods of making and using thereof
  • Multi-specific antibodies and methods of making and using thereof
  • Multi-specific antibodies and methods of making and using thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0105] Embodiment 1) the binding of tetraspecific antibody and EGFRvIII antigen

[0106] Binding of the tetraspecific antibodies listed in Table 1 to the EGFRvIII antigen expressed on the surface of the U87 cell line was assessed using the FACS method. Tetraspecific antibodies were incubated with the U87 cell line and then detected with a secondary anti-human antibody directly conjugated to the Alexa Fluor647 fluorescent dye. Cellular binding of tetraspecific antibodies was analyzed on a flow cytometer BD LSRFortessa. All antibodies tested bound the antigen with KD in the single digit and subnanomolar range (Table 2). The observed differences in binding were in the 3-fold range and were likely driven by the position of the binding domain within the molecule as well as interactions with neighboring domains.

[0107] Table 1 shows examples of tetraspecific antibodies with EGFRvIII tumor antigen binding domains. Table 2 shows binding to EGFRvIII antigen expressed in the U87 c...

Embodiment 2

[0113] Example 2): Binding of tetraspecific antibodies to EGFRvIII, 4-1BB, PD-L1 and CD3 protein antigens

[0114] The binding affinities and kinetics of the tetraspecific antibodies listed in Table 1 to their respective antigens were evaluated by surface plasmon resonance on a Fortebio Octet RED96 instrument. Antigens are immobilized on the surface of the sensor chip, and the antibodies to be tested flow over the immobilized antigens. All molecules showed high binding to antigen (Table 3). SI-39E29, SI-39E18 and SI-39E23 showed lower binding to CD3 e / d antigen than other antibodies tested. Table 3 shows the binding of the four specific antibodies listed in Table 1 to EGFRvIII, 4-1BB, PD-L1 and CD3 antigens.

[0115] Table 3. Binding to EGFRvIII, 4-1BB, PD-L1 and CD3 antigens.

[0116] Table 3A.

[0117]

[0118] Table 3B.

[0119]

Embodiment 3

[0120] Example 3) Redirected PBMC cytotoxicity against the astrocytoma cell line U87 transfected with EGFRvIII

[0121] The tetraspecific antibodies listed in Table 1 were evaluated for their ability to redirect PBMCs to lyse U87 transfected with the EGFRvIII tumor cell line (U87vIII). PBMCs were separated by Ficoll gradient. The U87vIII tumor cell line stably expresses nuclear-localized red fluorescent protein (RFP) delivered by lentiviral transduction (Sartorius). U87vIII tumor cells were co-cultured with PBMCs. Tumor cell lysis was assessed by counting RFP-labeled tumor cell nuclei. Images were acquired on a live cell imager IncuCyte (Sartorius). SI-39E18 and SI-39E13 tetraspecific antibodies showed the highest potency at 96 hours, followed by SI-39E10. SI-39E4, SI-39E23 and SI-39E29 showed lower potency in this study than the other antibodies listed in Table 1 (Figure 2).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The disclosure provides a tetra-specific antibody monomer having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal, a first scFv domain at the N-terminal, a Fabdomain, a Fc domain, a second scFv domain, and a third scFv at the C-terminal, wherein the first scFv domain, the Fab domain, the second scFv domain, and the third scFv domain each has a binding specificity against a different antigen. In one embodiment, the antigen is a tumor antigen, an immune signaling antigen, or a combination thereof. Multi-specific antibodies comprising the disclosed tetra-specific antibodies are also provided.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of U.S. Provisional Patent Application No. 62524557, filed June 25, 2017, which is expressly incorporated herein by reference in its entirety. technical field [0003] The present disclosure relates generally to the field of biotherapeutics, and more specifically to making and using multispecific antibodies. Background technique [0004] Cancer cells develop various strategies to evade the immune system. One of the mechanisms underlying immune evasion is reduced recognition of cancer cells by the immune system. Defective presentation of cancer-specific antigens, or their lack thereof, leads to immune tolerance and cancer progression. In the presence of efficient immune recognition, tumors use other mechanisms to avoid elimination by the immune system. Immunocompetent tumors create an inhibitory microenvironment that downregulates the immune response. Multiple players are involved...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28A61K39/395G01N33/68
CPCC07K16/2809C07K16/2878C07K16/2827C07K16/2863A61P35/00A61P35/02A61K2039/505C07K2317/31C07K2317/622C07K2317/55C07K2317/52C07K2317/60C07K2317/92C07K16/2803C07K2319/33
Inventor 朱义欧勒·奥尔森夏冬大卫·耶利曼卡特里娜·贝科娃安妮玛丽·卢梭比尔·布雷迪布莱尔·伦肖布莱恩·科瓦切维奇梁玉高泽人
Owner SYSTIMMUNE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com